2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 Post author:alarpharm Post published:9 . 5 . 2022 Post category:Media releases You Might Also Like 2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022 2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S) 23 . 8 . 2023 2023/10/12 Receives the notice of exercising the Option in the license agreement of ALA-1000 and related products from INDIVIOR UK LIMITED 12 . 10 . 2023 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022
2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022
2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S) 23 . 8 . 2023
2023/10/12 Receives the notice of exercising the Option in the license agreement of ALA-1000 and related products from INDIVIOR UK LIMITED 12 . 10 . 2023
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022
